Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The
current standard treatment for this disease is radiation therapy to the brain. The goal of
the current study is to test whether the combination of orally administered HYCAMTIN capsules
and whole brain radiation therapy will prolong the survival time of patients with this
potentially serious condition.